Skip to main content
. 2023 May 26;5(3):100376. doi: 10.1016/j.ocarto.2023.100376

Table 2.

Baseline and 6-month outcome measures stratified by clinical OA status.

Outcome Baseline
6-Mo
P-value
OA (−) OA (+) Combined OA (−) OA (+) Combined

Body Composition
 BMI (kg/m2) 35.3 ± 4.8 34.2 ± 4.6 34.6 ± 4.7 33.0 ± 4.4 31.7 ± 4.5 32.1 ± 4.4 P < 0.0001
 Body Mass (% change) - −5.8 ± 4.1 −6.3 ± 4.0 −6.2 ± 4.0 P < 0.0001
 Lean Body Mass (%) 56.0 ± 6.0 56.3 ± 5.4 56.2 ± 5.6 58.8 ± 6.0 59.7 ± 6.0 59.4 ± 6.0 P < 0.0001
 Fat Mass (%) 44.0 ± 6.0 43.6 ± 5.7 43.8 ± 5.7 41.2 ± 6.0 40.4 ± 5.9 40.7 ± 5.9† P < 0.0001
 Lean Body Mass (kg) 54.2 ± 10.4 53.6 ± 10.0 53.8 ± 10.0 54.2 ± 10.6 52.9 ± 9.4 53.3 ± 9.8 P = 0.224
 Fat Mass (kg) 43.6 ± 9.2 41.2 ± 9.7 42.0 ± 8.9 37.8 ± 7.6 36.0 ± 8.8 36.6 ± 8.4 P < 0.0001
Biomarkers
 Adiponectin Ln(ng/mL) 9.5 ± 0.7 9.7 ± 0.8 9.6 ± 0.8 9.6 ± 0.7 9.7 ± 0.8 9.7 ± 0.7 P = 0.0480
 COMP Ln(ng/mL) 14.7 ± 0.5 14.5 ± 0.4 14.7 ± 0.4 14.4 ± 0.4 14.4 ± 0.4 14.4 ± 0.4 P < 0.0001†,‡
 CRP Ln(ng/mL) 10.6 ± 0.6 10.4 ± 0.5 10.5 ± 0.6 10.7 ± 0.7 10.3 ± 0.6 10.5 ± 0.5 P = 0.710
 IL-6 Ln(pg/mL) 2.0 ± 0.5 1.9 ± 0.7 1.9 ± 0.6 1.9 ± 0.5 1.8 ± 0.9 1.9 ± 0.8 P = 0.414
 TNF-α Ln(pg/mL) 1.5 ± 0.7 1.2 ± 1.0 1.3 ± 0.9 1.4 ± 0.7 1.2 ± 0.8 1.3 ± 0.8 P = 0.752
Physical Function
 SPPB (score) 9.4 ± 1.2 9.1 ± 1.3 9.2 ± 1.3 11.3 ± 1.1 11.1 ± 1.5 11.1 ± 1.4 P < 0.0001
 6-Minute walk (m) 474.4 ± 124.0 499.3 ± 86.7 485.4 ± 101.4 553.4 ± 77.3 524.3 ± 79.7 520.6 ± 99.9 P = 0.091
 8-Foot up and go (sec) 7.6 ± 1.6 7.7 ± 2.0 7.6 ± 2.9 6.2 ± 0.9 7.1 ± 1.6 6.8 ± 1.4 P < 0.0001
 10-Chair Stands (sec) 24.2 ± 7.7 25.5 ± 6.1 25.1 ± 6.6 19.3 ± 4.0 22.2 ± 6.4 21.2 ± 5.8 P < 0.0001
 Left Hand Strength (kg) 24.8 ± 8.3 23.7 ± 8.6 24.1 ± 8.4 25.3 ± 6.8 22.8 ± 9.0 23.7 ± 8.2 P = 0.830
 Right Hand Strength (kg) 25.9 ± 7.3 25.0 ± 8.9 25.4 ± 8.3 26.5 ± 7.3 24.5 ± 10.1 25.3 ± 9.1 P = 0.910

Notes: Since analysis of dietary arm (i.e., standard protein vs higher protein) did not detect any effect of dietary arm on the outcome measures, subjects were stratified only by clinical OA status.

p < 0.05 for group change from baseline to 6-Mo (See: ‘Pre-Post Changes’).

p < 0.05 for between OA group change from baseline to 6-Mo (See: ‘Impact of OA on Outcome Measures’).

OA (−) n = 20, OA (+) n = 39.

Data reported as mean ± SD or total number (%). Bolding highlights the differences in grouped values which were found to be different between the baseline and 6-Month timepoints.